The global cancer drugs market was valued at $87.6 Billion in 2017 and is forecast to grow at a modest xx.2 % CAGR between 2018 and 2025, culminating in 2025 global sales of $135.5 Billion.
As per WHO, 8.8 million people worldwide died from cancer in 2015. The most common causes of cancer death are cancers of Lung (1.69 million deaths), Liver (788 000 deaths), Colorectal (774 000 deaths), Stomach (754 000 deaths), Breast (571 000 deaths). Nearly 1 out of every 6 deaths globally. 30-50% of cancer cases can be prevented. It’s causing an annual economic cost of USD 1.16 trillion globally. Cancer-causing infections, such as hepatitis and human papillomavirus (HPV), are responsible for up to 25% of cancer cases in low- and middle-income countries.
Cancer arises from the transformation of normal cells into tumor cells in a multistage process that generally progresses from a pre-cancerous lesion to a malignant tumor. This can result in individuals’ genetic factors along with physical carcinogens, chemical carcinogens, and biological carcinogens.
“Optimal Price Point (OPP) for Cancer Drugs”
Estimated Average product/ service cost – $ xx globally. However, with improving access and availability of options, OPP and range of acceptable Prices (RAP) are going to change. We at Ameri Research continuously track these prices with our proprietary pricing model.
Due to the wide array of products available in the market, pricing, positioning, and sales channel optimization play a vital role in the success of a product. On an average, in the U.S., the cancer drugs are available at USD xxx- USD xxxx. However, the high-end products are available at much higher prices. The prices in emerging countries and developed countries vary significantly due to the difference in purchasing power and availability of latest products.
Cancer Drugs Market by “Disease Type”
We have segmented the Cancer Drugs market into Blood Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Liver Cancer, Lung Cancer, Kidney Cancer. Lung Cancer is the major cause of death due to cancer followed by Liver and Breast Cancer. We are estimating breast cancer to grow at a CAGR of 25.8% during the forecast period. With an aging population and change in lifestyle, the incidence of cancer is rising steadily.
Cancer Drugs Market by “Treatment Categories”
We have segmented the Cancer Drugs market by treatment into Chemotherapy ((Alkylating Agents, and Antimetabolites), Targeted Therapy (Monoclonal Antibodies and Tyrosine Kinase Inhibitors), Immunotherapy and Hormonal. We are observing newer biologic into immunotherapy shaping the Cancer Drugs. Advancing novel therapeutic agents for the treatment of malignancy proving costly and lengthy process. Cost estimates for de novo drug discovery range from $500 million to $2 billion.
Cancer Drugs Market by “Distribution Channel”
We have segmented the cancer drugs market based on distribution channel as Hospitals, Drug Store, Specialty Pharmacy, E-Pharmacy. Majority of products channelized through hospitals (Particularly Chemo, Surgery and Radiation). However, we are observing the increased role of specialized pharmacy and E-pharmacy in the distribution/ dispensation of treatment drugs. Patient education to increase compliance and Persistency plays a key role in the outcome. Many payors are linking reimbursement to the outcome.
North America accounted for the maximum revenue share of over 70% in 2017 due to increased patient number, lifestyle followed by availability of treatment options, better reimbursement plan, and RND. Followed by EU- Top 5 countries contribute $X.6 Billion in 2017 and expected to reach $x.5 Billion by 2023.
With changing lifestyle in developing countries and availability of treatment option, we are observing a rise in patient numbers in developing countries. However, these markets represent a minuscule percentage of the overall market.
“Competitive Landscape” and “Merger & Acquisition Insights”
The key market participants include AstraZeneca, Bristol Myers Squibb, Bayer AG, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceuticals, Takeda Pharmaceutical, Merck & Co., Genentech Inc., Boehringer Ingelheim, and F. Hoffman-La Roche Ltd. The growing investment in research and development is driving the companies to innovate, stay market relevant and retain their share. Moreover, there are several startup companies working on stem cell and biologic research, and these companies are considered as strategic assets for merger and acquisition. Non-platinum based PARP inhibitors and VEGF inhibitors are changing the treatment paradigm for cancer significantly. We are observing a new drug development for cancer ONX-0801 is in Phase1. Some of the most notable transactions in the recent past include,
- Novogen Limited, an oncology-focused biotechnology company, becomes Kazia Therapeutics Limited.
- Tesaro’s acquisition with prospective bidder has diminished in event of news that rival drugs from AstraZeneca and Clovis are just as effective as Tesaro’s niraparib.
Cancer Drugs Market by Disease Type (Revenue, Million, 2014 – 2025)
- Blood Cancer
- Breast Cancer
- Prostate Cancer
- Colorectal Cancer
- Cervical Cancer
- Liver Cancer
- Lung Cancer
- Kidney Cancer
Cancer Drugs Market by Treatment Categories (Revenue, Million, 2014 – 2025)
- Alkylating Agents
- Targeted Therapy
- Monoclonal Antibodies
- Tyrosine Kinase Inhibitors
Cancer Drugs Market by Distribution Channel (Revenue, Million, 2014 – 2025)
- Drug Store
- Specialty Pharmacy
Cancer Drugs Market Regional Outlook (Revenue, USD Million, 2014- 2025)
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
- South Africa
- Saudi Arabia
Cancer Market, Cancer Market Analytics, Cancer Market Share, Cancer Market Research, Cancer Market Forecast, Cancer Market Insight, Cancer Market Trend, Cancer Market Value,Cancer Market Size, Cancer Market Analysis, Cancer Market Survey, Blood Cancer Drugs Market, Oncology Drugs Market Analytics, Oncology Drugs Market Share, Oncology Drugs Market Research, Oncology Drugs Market Forecast, Oncology Drugs Market Insight, Oncology Drugs Market Trend, Oncology Drugs Market Value,Oncology Drugs Market Size, Oncology Drugs Market Analysis, Oncology Drugs Market Survey